Autolus Therapeutics Plc's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 3.4, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Autolus Therapeutics Plc in Jun 30 2026 quarter, has decreased to 107 days, compared to 119 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 483 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 3240, from overall ranking in the first quarter 2026 at 3704.

What is Receivable Turnover Ratio?
What is Autolus Therapeutics Plc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AUTL Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	65.14 %	134.95 %	4828.66 %	5508.7 %	2753.61 %
Y / Y Revenue Change	118.37 %	191.89 %	83655.17 %	-	-
Receivable Turnover Ratio (TTM)	3.4	3.08	3	2.69	2.77
AUTL's Total Ranking	# 3240	# 3704	# 3426	#	#
Accounts Receivable average collection period days	107	119	122	136	132
Seq. Receivable Change	30.22 %	38.87 %	-25.64 %	22.82 %	85.27 %
Seq. Revenue Change	74.27 %	7.94 %	14.6 %	1.3 %	132.94 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 56
Healthcare Sector	# 484
Overall Market	# 3240

Receivable Turnover Ratio Statistics
High	Average	Low
3.04	1.75	0.43
(Jun 30 2026)		(Dec 31 2022)

AUTL Company Profile • Back to AUTL Efficiency Comparisons • Compare AUTL Receivables Turnover Ratio to its Competitors

Financial Statements
Autolus Therapeutics Plc's Accounts Receivable	$ 45 Millions	Visit AUTL's Balance sheet
Autolus Therapeutics Plc's Sales TTM	$ 117 Millions	Visit AUTL's Income Statement
Sources of AUTL's Revenues		Visit AUTL's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
AUTL's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
AUTL's Growth Rates	AUTL's Roa	AUTL's Inventory Turnover Ratio	AUTL's Dividend Comparisons
AUTL's Profitability Ratios	AUTL's Roi	AUTL's Asset Turnover Ratio	AUTL's Dividend Growth
AUTL's Valuation Ratios	AUTL's Roe	AUTL's Financial Strength Ratios	AUTL's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Travere Therapeutics Inc	7.10	$ 591.330 Millions	$ 83.339 Millions
Angiodynamics Inc	7.08	$ 317.726 Millions	$ 44.853 Millions
Pulmonx Corporation	7.07	$ 87.393 Millions	$ 12.356 Millions
Sutro Biopharma Inc	6.98	$ 45.702 Millions	$ 6.545 Millions
Edwards Lifesciences Corporation	6.98	$ 6,512.500 Millions	$ 933.400 Millions
Beyond Air Inc	6.98	$ 6.677 Millions	$ 0.957 Millions
Quidelortho Corp	6.92	$ 2,674.200 Millions	$ 386.400 Millions
Myriad Genetics Inc	6.91	$ 805.900 Millions	$ 116.650 Millions
Ceribell Inc	6.90	$ 101.804 Millions	$ 14.749 Millions
Stryker Corp	6.89	$ 25,837.000 Millions	$ 3,749.000 Millions
Nephros Inc	6.83	$ 21.686 Millions	$ 3.173 Millions
Medpace Holdings Inc	6.82	$ 2,782.288 Millions	$ 408.189 Millions
Opko Health Inc	6.79	$ 587.896 Millions	$ 86.589 Millions
Atara Biotherapeutics Inc	6.79	$ 6.452 Millions	$ 0.950 Millions
Rapid Micro Biosystems Inc	6.76	$ 34.545 Millions	$ 5.111 Millions
Universal Health Services Inc	6.75	$ 18,114.487 Millions	$ 2,683.492 Millions
3m Company	6.72	$ 25,180.000 Millions	$ 3,747.750 Millions
Phibro Animal Health Corporation	6.70	$ 1,516.861 Millions	$ 226.555 Millions
Eton Pharmaceuticals Inc	6.67	$ 105.279 Millions	$ 15.783 Millions
Neuropace Inc	6.65	$ 98.620 Millions	$ 14.834 Millions
Aspira Women s Health inc	6.65	$ 9.029 Millions	$ 1.358 Millions
Bionano Genomics Inc	6.62	$ 30.176 Millions	$ 4.556 Millions
Liquidia Corporation	6.61	$ 450.907 Millions	$ 68.198 Millions
Pmgc Holdings Inc	6.57	$ 2.579 Millions	$ 0.393 Millions
Embecta Corp	6.50	$ 1,019.700 Millions	$ 156.775 Millions
Moderna Inc	6.49	$ 2,228.000 Millions	$ 343.250 Millions
Adaptive Biotechnologies Corporation	6.38	$ 308.081 Millions	$ 48.254 Millions
Iradimed Corporation	6.38	$ 86.339 Millions	$ 13.533 Millions
Edap Tms Sa	6.34	$ 111.051 Millions	$ 17.522 Millions
Syndax Pharmaceuticals Inc	6.32	$ 252.004 Millions	$ 39.902 Millions

Date modified: 2026-09-04T10:02:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.